Destination XL Group, Inc. to Announce Third Quarter 2025 Financial Results on Thursday, December 4, 2025 Company to Webcast Conference Call Live at 9:00 a.m. ET GlobeNewswire November 12, 2025 CANTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (NASDAQ: DXLG), the leading integrated commerce retailer of Big + Tall men's clothing […]

PayCargo and IBS Software Strengthen Long-Term Collaboration to Advance Air Cargo Long-term partners set new standard for digital infrastructure powering the future of air cargo GlobeNewswire November 12, 2025 CORAL GABLES, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) — PayCargo, the trusted logistics payment platform, and IBS Software, a leading SaaS solutions provider to the travel

Microbix Partners with SEKISUI Diagnostics to Support COVID/Flu Tests Supporting the Metrix(R) Molecular Point-of-Care Assay GlobeNewswire November 12, 2025 MISSISSAUGA, Ontario, Nov. 12, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix(R)), a life sciences innovator, manufacturer, and exporter, and SEKISUI Diagnostics, LLC (SEKISUI), a global manufacturer of innovative diagnostic tests, reagents,

Apellis Announces 5-Year GALE Data Showing SYFOVRE(R) (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years GlobeNewswire November 12, 2025 WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE(R)

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference GlobeNewswire November 12, 2025 CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the 2025 Jefferies London Healthcare Conference on

GlobalFoundries Reports Third Quarter 2025 Financial Results GlobeNewswire November 12, 2025 MALTA, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) — GLOBALFOUNDRIES Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the third quarter ended September 30, 2025. Key Third Quarter Financial Highlights Revenue of $1.688 billion Gross margin of 24.8% and Non-IFRS gross margin(1) of

AlphaTON's Cyncado Therapeutics and Australia's ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans ADDRI-sponsored trial in Australia planned to enroll approximately 50 patients, led by A/Prof Steven Kao and Dr Melvin Chin; part of Cyncado's international program for mesothelioma GlobeNewswire November 12, 2025 Dover, DE and Sydney, Australia, Nov. 12, 2025

OTC Markets Group Welcomes District Metals Corp. to OTCQX GlobeNewswire November 12, 2025 NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced District Metals Corp. (TSX-V: DMX; OTCQX: DMXCF), a disciplined, science-based exploration and development company, has

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER(R)) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps GlobeNewswire November 12, 2025 Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as

Sitryx presents new preclinical data highlighting PKM2 as a promising metabolic target for the treatment of atopic dermatitis at the Inflammatory Disease Skin Summit 2025 GlobeNewswire November 12, 2025 Preclinical data highlight that PKM2 modulation inhibits several important mechanisms underlying atopic dermatitis pathology SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease